Search clinical trials for: ISIS-GCCRRx

Total 263 results

Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, South Africa
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Type 2 Diabetes Mellitus

Canada, Romania, South Africa
Ionis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Type 2 Diabetes

Austria
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Elevated Lipoprotein(a)

Netherlands, United Kingdom, Denmark, Germany, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
Biogen

Completed

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States
Biogen

Terminated

A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). (EMBRACE)

Spinal Muscular Atrophy

United States, Germany
Ionis Pharmaceuticals, Inc.

Completed

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients (FGFR4-CS2)

Obesity

United States
Biogen

Completed

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) (SMNRx)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Type 2 Diabetes Mellitus

Russian Federation, Poland
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Spinal Muscular Atrophy

United States
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Ionis Pharmaceuticals, Inc.
Elan Pharmaceuticals; Hepasense

Completed

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

Hepatitis C, Chronic

United States
Ionis Pharmaceuticals, Inc.

Completed

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Type 2 Diabetes Mellitus

Poland, Romania, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Healthy Participants

United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Renal Impairment

United States, Canada
European Organisation for Research and Treatment...

Completed

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Lung Cancer | Melanoma (Skin)

France, Netherlands, Norway, Belgium, Switzerland, United Kingdom, Germany, Denmark, Austria
Ionis Pharmaceuticals, Inc.

Completed

Safety Study of ISIS 325568 in Healthy Volunteers

Type 2 Diabetes Mellitus

Netherlands
Biogen

Active, not recruiting

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE)

Spinal Muscular Atrophy

United States, Taiwan, Israel, Australia, Qatar, United Kingdom, Turkey, Italy, Germany, Argentina, Canada
Ionis Pharmaceuticals, Inc.
Bayer

Completed

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

End-stage Renal Disease (ESRD)

Canada
National Institute of Diabetes and Digestive and...

Completed

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

Lipodystrophy

United States
AstraZeneca
Ionis Pharmaceuticals, Inc.

Completed

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma Metastatic

Korea, Republic of, Taiwan, Hong Kong, Japan
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada, France, Germany, United Kingdom, Netherlands
Ionis Pharmaceuticals, Inc.

Available

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Mild Alzheimer's Disease

United Kingdom, Netherlands, Germany, Sweden, Canada, Finland
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

United States, Canada, Germany, Israel, Italy, South Africa, Spain, United Kingdom, Brazil, France, Netherlands
Biogen

No longer available

Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Infantile-onset Spinal Muscular Atrophy

New Zealand, Colombia, Turkey
Ionis Pharmaceuticals, Inc.
AstraZeneca

Completed

Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Lymphoma | DLBCL | Advanced Cancers

United States
Ionis Pharmaceuticals, Inc.

Completed

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

United States
Smith, Timothy R., M.D.
Ionis Pharmaceuticals, Inc.; Clinvest Research, LLC

Completed

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

Chronic Migraine

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Rheumatoid Arthritis

Canada, Russian Federation
Ionis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Hereditary Angioedema

Netherlands, United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Terminated

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Familial Partial Lipodystrophy

United States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

Venous Thromboembolism

Bulgaria, Canada, Latvia, Russian Federation, Ukraine
Biogen

Active, not recruiting

A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND)

Muscular Atrophy, Spinal

United States, Spain, Germany, Italy, Israel
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Withdrawn

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

Canada
Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Severe Hypertriglyceridemia

United States, South Africa, Spain, Israel, Australia, Sweden, Netherlands, Canada, Poland, Denmark, Hungary, Bulgaria, Czechia, Italy, France, Norway, New Zealand, Slovakia, Turkey
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Ionis Pharmaceuticals, Inc.

Available

Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

Hereditary Angioedema
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Familial Chylomicronemia Syndrome

United States, Canada, Sweden
Ionis Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Beta Thalassemia Intermedia

Australia, Thailand, Greece, Lebanon, Turkey
Brigham and Women's Hospital
GlaxoSmithKline; Ionis Pharmaceuticals, Inc.

Withdrawn

The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

Amyloidosis
Biogen

Completed

Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection (PANDA)

Muscular Atrophy, Spinal

China
Ionis Pharmaceuticals, Inc.

Completed

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

Healthy Volunteers

Canada
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden

3

Subscribe